Skip to Main Content

Paper Details

Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.
JAMA Cardiology
48
2019
Canakinumab, Cardiovascular Events, MI, Participants, canakinumab, cardiovascular, cardiovascular events, high-sensitivity C-reactive protein, hs-CRP, lung cancer, myocardial infarction, patients
Author NameAffiliation
Mark A HlatkyStanford University School of Medicine
Mark A HlatkyStanford University
  • 1 - 2

Datasets

Release 1.2